The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer.

摘要: Epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) represents a distinct disease entity whose molecular phenotype predicts exquisite sensitivity to the reversible EGFR-tyrosine kinase inhibitors (TKIs) gefitinib or erlotinib. However, primary acquired resistance these agents remains major clinical problem. Afatinib is novel dual irreversible EGFR/HER2 TKI that has been shown in preclinical studies potentially prevent, delay overcome EGFR-TKIs. On this basis, LUX-Lung trial program recently launched for testing molecule advanced NSCLC patients. Notably, early results from randomized 1 indicate afatinib significantly prolongs progression-free survival compared with placebo pretreated patients clinically other hand, 2 shows highly active EGFR-mutant subgroup of While preliminary data open new exciting scenario future development anti-EGFR therapies NSCLC, ongoing trials will definitively establish role treatment NSCLC.